The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial
The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Objective: Preclinical studies, observational studies, and clinical trials suggest that thiazolidinediones (TZDs) reduce bone mineral density (BMD) and increase fracture risk. Most of the evidence on the skeletal effects of TZDs is from studies of rosiglitazone. We set out to investigate the magnitude and etiology of the adverse skeletal effects of pioglitazone. Design: Double-blind, randomized controlled trial. Trial registration: Australia New Zealand Clinical Trials Registry, actr.org.au Identifier: ACTRN12607000610437, date of registration 28/11/07. Methods: A total of 86 people with type 2 diabetes mellitus (T2DM) or impaired glucose tolerance (IGT), median age 64 years, were randomized to receive either pioglitazone 30 mg/day or placebo for 1 year, in addition to their usual diabetes treatments. The primary outcome was change in lumbar spine BMD; secondary outcomes included changes in BMD at other sites and in biochemical markers of bone turnover. Results: Change in spine BMD was not altered by treatment with pioglitazone (Ptreatment×time=0.5). After 1 year, the mean (95% CI) between-groups difference in lumbar spine BMD was −0.7% (−2.1, 0.7). Pioglitazone increased bone loss at the proximal femur (Ptreatment×time=0.03). After 12 months, the between-groups difference in total hip BMD was −1.2% (−2.1, 0.2). Pioglitazone did not alter change in BMD at other skeletal sites, nor did it affect changes in the levels of either of the biochemical markers of bone turnover, procollagen type 1 N-terminal propeptide, or β-C-terminal telopeptide of type 1 collagen. Conclusions: Over 1 year, treatment with pioglitazone 30 mg/day did not produce consistent effects on either BMD or bone turnover in people with T2DM or IGT. The mechanism(s) by which pioglitazone increases fracture risk in T2DM is unclear.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The mechanism is uncertain, and studies have not shown a consistent effect of the drug on bone density.44,45”
From Pioglitazone after Ischemic Stroke or Transient Ischemic Attack (2016) · cites this paper as [44]
Citations
Cites
Marshall, D., Johnell, O., & Wedel, H. (1996) · BMJ · doi:10.1136/bmj.312.7041.1254 · Cited by 3,709
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Vestergaard, P. (2007) · Osteoporosis International · doi:10.1007/s00198-006-0253-4 · Cited by 1,808
Tang, B. M., Eslick, G. D., Nowson, C., Smith, C., & Bensoussan, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61342-7 · Cited by 1,248
Nissen, S. E., & Wolski, K. (2010) · Archives of Internal Medicine · doi:10.1001/archinternmed.2010.207 · Cited by 594
Older Women With Diabetes Have a Higher Risk of Falls
Schwartz, A. V., Hillier, T. A., Sellmeyer, D. E., Resnick, H. E., Gregg, E., Ensrud, K. E., Schreiner, P. J., Margolis, K. L., Cauley, J. A., Nevitt, M. C., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.10.1749 · Cited by 576
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Grey, A., Bolland, M., Gamble, G., Wattie, D., Horne, A., Davidson, J., & Reid, I. R. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2646 · Cited by 401
Self-citationBone, sweet bone—osteoporotic fractures in diabetes mellitus
Hamann, C., Kirschner, S., Günther, K.-P., & Hofbauer, L. C. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.233 · Cited by 380
Use of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355
Leslie, W. D., Rubin, M. R., Schwartz, A. V., & Kanis, J. A. (2012) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1759 · Cited by 352
JAMES, K. E., BLOCH, D. A., LEE, K. K., KRAEMER, H. C., & FULLER, R. K. (1996) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19960715)15:13<1421::aid-sim266>3.0.co;2-h · Cited by 286
Zinman, B., Haffner, S. M., Herman, W. H., Holman, R. R., Lachin, J. M., Kravitz, B. G., Paul, G., Jones, N. P., Aftring, R. P., Viberti, G., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0572 · Cited by 180
A Bone Structural Basis for Fracture Risk in Diabetes
Melton, L. J., Riggs, B. L., Leibson, C. L., Achenbach, S. J., Camp, J. J., Bouxsein, M., Atkinson, E. J., Robb, R. A., & Khosla, S. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0639 · Cited by 161
Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men
Yaturu, S., Bryant, B., & Jain, S. K. (2007) · Diabetes Care · doi:10.2337/dc06-2606 · Cited by 156
Glintborg, D., Andersen, M., Hagen, C., Heickendorff, L., & Hermann, A. P. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-2249 · Cited by 133
The Risk of Fractures Associated with Thiazolidinediones: A Self-controlled Case-Series Study
Douglas, I. J., Evans, S. J., Pocock, S., & Smeeth, L. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000154 · Cited by 112
Bilezikian, J. P., Josse, R. G., Eastell, R., Lewiecki, E. M., Miller, C. G., Wooddell, M., Northcutt, A. R., Kravitz, B. G., Paul, G., Cobitz, A. R., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4018 · Cited by 99
A Cohort Study of Thiazolidinediones and Fractures in Older Adults with Diabetes
Solomon, D. H., Cadarette, S. M., Choudhry, N. K., Canning, C., Levin, R., & Stürmer, T. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-2157 · Cited by 93
Thiazolidinedione‐induced skeletal fragility – mechanisms and implications
Grey, A. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00931.x · Cited by 90
Self-citationBorges, J. L. C., Bilezikian, J. P., Jones‐Leone, A. R., Acusta, A. P., Ambery, P. D., Nino, A. J., Grosse, M., Fitzpatrick, L. A., & Cobitz, A. R. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01461.x · Cited by 90
Changes in Glitazone Use Among Office-Based Physicians in the U.S., 2003–2009
Cohen, A. J., Rabbani, A., Shah, N. D., & Alexander, G. C. (2010) · Diabetes Care · doi:10.2337/dc09-1834 · Cited by 56
Lincoff, A. M., Wolski, K., Nicholls, S. J., & Nissen, S. E. (2007) · JAMA · doi:10.1001/jama.298.10.1180 · Cited by 52
Bone, H. G., Lindsay, R., McClung, M. R., Perez, A. T., Raanan, M. G., & Spanheimer, R. G. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4096 · Cited by 47
Berberoglu, Z., Yazici, A. C., & Demirag, N. G. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03784.x · Cited by 44
Rosiglitazone is not associated with an increased risk of bladder cancer
Tseng, C. (2013) · Cancer Epidemiology · doi:10.1016/j.canep.2013.03.013 · Cited by 21
Pioglitazone and the risk of bladder cancer
Hillaire‐Buys, D., & Faillie, J. (2012) · BMJ · doi:10.1136/bmj.e3500 · Cited by 18
Bone Effects of Rosiglitazone in HIV-Infected Patients With Lipoatrophy
Ross, A. C., Hileman, C. O., Brown, T. T., Fedarko, N. S., Storer, N. J., Labbato, D. E., & McComsey, G. A. (2012) · HIV Clinical Trials · doi:10.1310/hct1304-212 · Cited by 5
Research works printed but not linked: 1
- 2007, Journal of Clinical Endocrinology & Metabolism, 298, 1180
Cited by
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Risk of fracture with thiazolidinediones: An updated meta-analysis of randomized clinical trials
Zhu, Z.-N., Jiang, Y.-F., & Ding, T. (2014) · Bone · doi:10.1016/j.bone.2014.08.010 · Cited by 253
“In patients with impaired glucose tolerance, they slow the development of type 2 diabetes mellitus (T2DM); in patients with T2DM, TZDs improve glycemic control [1].”
Effects of diabetes drugs on the skeleton
Meier, C., Schwartz, A. V., Egger, A., & Lecka-Czernik, B. (2016) · Bone · doi:10.1016/j.bone.2015.04.026 · Cited by 174
Billington, E. O., Grey, A., & Bolland, M. J. (2015) · Diabetologia · doi:10.1007/s00125-015-3660-2 · Cited by 133
Self-citationPioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
Metadata
- Authors
- Grey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R.
- Affiliations
- University of Auckland (NZ)
- Corresponding author
- Grey, Andrew
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02
- Volume
- 170
- Issue
- 2
- Pages
- 255-262
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2116755767
- Cited by
- 43
- References
- 32
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 2 · 2020: 2 · 2019: 3 · 2018: 5 · 2017: 6 · 2016: 4 · 2015: 8 · 2014: 7
- FWCI
- 6.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
- Keywords
- pioglitazone, thiazolidinediones, type 2 diabetes, impaired glucose tolerance, bone mineral density, bone loss, fracture risk, bone turnover markers, lumbar spine, proximal femur, hip bone density, rosiglitazone
- MeSH terms
- Pioglitazone, Adult, Aged, Aged, 80 and over, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Humans, Lumbar Vertebrae, Male, Middle Aged, Risk, Spine, Bone Density, Bone Remodeling, Glucose Intolerance, Thiazolidinediones, Bone Density Conservation Agents, Fractures, Bone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.